127 results about "Epithelial cancer" patented technology

The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy.

The methods of the present invention allow for the non-invasive or minimally invasive isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling. Once isolated, the labeled epithelial cells or their labeled biochemical contents find use as kinetic biomarkers of diseases of epithelial tissues including epithelial cancers and epithelial proliferative disorders such as psoriasis and benign prostate hyperplasia. The biomarkers are useful in diagnosing a disease of epithelial tissue origin, monitoring therapeutic efficacy of compounds or combinations of compounds used to treat diseases of epithelial tissue origin, screen new chemical entities or biological factors or combinations of chemical entities or biological factors, or mixtures thereof, for therapeutic activity in animal models of diseases of epithelial tissue origin or in human clinical trials, or test for toxicity on epithelial tissues from exposure to therapeutic compounds or new chemical entities or environmental chemicals such as industrial or occupational chemicals, environmental pollutants, food additives, and cosmetics.

P5P can be used as effective treatments for the modulation of P2X7, IL-1β, and inflammation response, and for diseases in which prevention of P2X7-dependent pathways or prevention of release of IL-1β is desirable, such as epithelial cancer, leukemia, brain tumors, spinal cord injury, tuberculosis, Alzheimer's Disease, neurodegenerative diseases, autosomal recessive polycystic kidney disease, diabetes, including type I diabetes, prostate cancer, and osteoporosis, bone formation and resorption.

An extract of Scutellaria barbata D. Don is effective in the arrest of cancer cell growth in the G1 phase, the induction of apoptosis in cancer cells and the shrinking of solid cancers. The extract may be prepared as a pharmaceutical composition for administration to mammals for the treatment of solid cancers, such as epithelial cancers. Such epithelial cancers include breast cancer and ovarian cancers. The extract is obtained from Scutellaria barbata D. Don by contacting aerial portions of a plant from the species Scutellaria barbata D. Don with an aqueous or alcoholic solvent.

The invention relates to polypeptides and nucleic acids encoding these and to their use for the diagnosis, prevention and / or treatment of liver disorders and neoplastic disorders, especially cancer of the liver and other epithelial tissues, benign liver neoplasms such as adenoma and other proliferative liver disorders such as focal nodular hyperplasia (FNH) and cirrhosis. The invention further relates to methods of diagnosing and treating these disorders.

The present invention relates to the use of a mitochondrially targeted antioxidant, e.g. derivatives of vitamin E, coenzyme Q10 or a glutathione peroxidase mimetic, in the treatment and prevention of liver diseases and / or epithelial cancers. The present invention also relates to pharmaceutical compositions containing the antioxidant(s) intended for such use. Furthermore the invention relates to the manufacture of medicaments containing the antioxidant(s) useful for such prevention and treatment.

Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and / or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.

A method for detection and prognosis of breast cancer and other types of cancer. The method comprises detecting expression, if any, for both an Id-1 and an Id-2 genes, or the ratio thereof, of gene products in samples of breast tissue obtained from a patient. When expressed, Id-1 gene is a prognostic indicator that breast cancer cells are invasive and metastatic, whereas Id-2 gene is a prognostic indicator that breast cancer cells are localized and noninvasive in the breast tissue.

A product of the invention is a variety of hydroxycamptothecin derivative referred to as bipiperidine hydroxycamptothecin {chemical name: (+)-(4S)-4-ethyl-4-hydroxy-9 [ (4-piperidyl piperidine) carbonyl]-1H-pyrano [ 3 ', 4 ', 6 ', 7 '] butoprizine [1, 2-b] quinoline-3, 14-( 4H, 12H ) dione and (0-10) hydrate thereof}. The derivative is a broad-spectrum antineoplastic drug, and has curative effects on primary liver cancer, gastric cancer, head and neck adenoid epithelial cancer, leukemia, colon cancer, bladder cancer and other malignant tumors. The ipiperidine hydroxycamptothecin, salts thereof and (0-10) hydrate of the salts are prodrugs for hydroxycamptothecin and converted into closed hydroxycamptothecin in vivo, so as to overcome defects of open loop, poor effect and instability of a hydroxycamptothecin preparation (injection, lyophilized injection and oral preparation); and the derivative has good water solubility and is suitable for preparation of various types of preparations. The bipiperidine hydroxycamptothecin can be added with different salts to be prepared into different water-soluble compounds and hydrates thereof, is beneficial to preparation of various preparations, and has stable quality and curative effect obvious better than that of hydroxycamptothecin and preparation thereof. The bipiperidine hydroxycamptothecin, salts thereof, (0-10) hydrate of the salts and preparations thereof are in forms of tablet, capsule, particulate agent, oral liquid, injection, infusion solutions and lyophilized injection.

An extract of Scutellaria barbata D. Don is effective in the arrest of cancer cell growth in the G1 phase, the induction of apoptosis in cancer cells and the shrinking of solid cancers. The extract may be prepared as a pharmaceutical composition for administration to mammals for the treatment of solid cancers, such as epithelial cancers. Such epithelial cancers include breast cancer and ovarian cancers. The extract is obtained from Scutellaria barbata D. Don by contacting aerial portions of a plant from the species Scutellaria barbata D. Don with an aqueous or alcoholic solvent.

The present invention provides a monoclonal antibody for identifying HPV18 positive cervical epithelial cancer cells, and applications thereof. According to the present invention, with the monoclonal antibody, the cervical cancer biomarker HPV18E7 protein in the tumor cells can be detected in a highly specific manner so as to distinguish between the cancerous cervical epithelial cells and the abnormal cervical epithelial cells or non-cancerous cervical epithelial cells and provide basis for the accurate diagnose of the cancer caused by the HPV infection, such that the treatment can be timely taken, the cancer occurrence or cancer spreading can be prevented, and the suffering of patients can be alleviated.

The current invention provides Progastrin peptides that specifically bind Annexin A2 overexpressed by epithelial cancers. The invention includes isolated homing Progastrin peptides conjugated to an imaging agent and methods of using the same for the diagnosis of epithelial cancers. Also encompassed are Progastrin peptides conjugated to cytotoxic agents such as Camptothecin, Doxorubicin, Paclitaxel and derivatives thereof, and methods of treating epithelial cancer using the same.

Epithelial cancer screening can include a staining tissue with a cancer targeting agent, identifying a potentially cancerous lesion using fluorescence imaging, and imaging the potentially cancerous lesion for a cancer diagnosis using optical coherence tomography.

An extract of Scutellaria barbata D. Don is effective in the arrest of cancer cell growth in the G1 phase, the induction of apoptosis in cancer cells and the shrinking of solid cancers. The extract may be prepared as a pharmaceutical composition for administration to mammals for the treatment of solid cancers, such as epithelial cancers. Such epithelial cancers include breast cancer and ovarian cancers. The extract is obtained from Scutellaria barbata D. Don by contacting aerial portions of a plant from the species Scutellaria barbata D. Don with an aqueous or alcoholic solvent.

The invention belongs to the technical field of cell detection apparatus, and relates to a micro-fluidic chip used for simultaneous detection of bladder cancer cells, calculi, blood cells, and bacteria in urine. The micro-fluidic chip is composed of a lower sample channel layer and an upper pneumatic microvalve layer used for controlling on-off of sample channels; the lower sample channel layer is composed of an urine sample inlet, an urine sample main channel, and an urine sample outlet liquid storage tank; a plurality of detecting units, including an urinary calculi interception unit, an urinary bladder transitional epithelial cancer detection unit, an urinary bladder adenocarcinoma cell detection unit, an urinary bladder squamous carcinoma cell detection unit, a blood cell detection unit, and a bacterium detection unit , are arranged on the urine sample main channel; and the detecting units are connected in series, and are arranged in a circular symmetry manner. The micro-fluidic chip is high in specificity and sensitivity, can be used for determining that whether a patient suffers from bladder cancer and urinary tract symptoms just via detection on urine, and is a cheap high-efficiency urine detection tool.

Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and / or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.

An extract of Scutellaria barbata D. Don is effective in the arrest of cancer cell growth in the G1 phase, the induction of apoptosis in cancer cells and the shrinking of solid cancers. The extract may be prepared as a pharmaceutical composition for administration to mammals for the treatment of solid cancers, such as epithelial cancers. Such epithelial cancers include breast cancer and ovarian cancers. The extract is obtained from Scutellaria barbata D. Don by contacting aerial portions of a plant from the species Scutellaria barbata D. Don with an aqueous or alcoholic solvent.

EMT signatures and markers useful for characterizing the status of epithelial cancers and for predicting drug responses in patients having non-small cell lung cancer are provided together with methods of using the same.

The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and / or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.

The present invention provides a cell culture medium with which serum-free long-term culture of an epithelial stem cell, an epithelial cancer cell, or a tissue containing at least one thereof can be achieved. The cell culture medium of the present invention includes: a Wnt agonist composed of a complex of Wnt protein and afamin, which is a substance capable of stabilizing the Wnt protein, and R-spondin; and at least one selected from the group consisting of a mitogenic growth factor, a bone morphogenetic protein (BMP) inhibitor, a transforming growth factor-β (TGF-β) inhibitor, and a p38 inhibitor.

Isolated compounds and combinations of isolated compounds isolated from Scutellaria barbata D. Don are effective in the generation of reactive oxygen species, induction of DNA damage and induction of apoptosis in cancer cells. The compounds and combinations may be prepared as pharmaceutical compositions for administration to mammals, such as humans, for the treatment of solid cancers, such as epithelial cancers. Such epithelial cancers include breast cancer and ovarian cancers.

The present invention refers to active substance combinations comprising of a nucleoside analog or antimetabolic agent like Gemcitabine, and either a Nodal / Activin inhibitor or a SHH-Inhibitor and an mTOR-inhibitor, medicaments comprising the same and the use of the active substance combinations in the treatment of cancer, especially of epithelial cancer.

The invention discloses a siRNA sequence relating to inhibition of survivin gene expression. The siRNA sequence is composed of a positive-sense strand and an anti-sense strand which have the following nucleotide sequences, the positive-sense strand is 5'-GGCCCUUGUCUAAGUGCAA-3', and the anti-sense strand is 5'-UUGCACUUAGACAAGGGCC-3'. The siRNA sequence has broad-spectrum siRNA antitumor effect, and has good inhibiting effect on breast cancer, lung cancer, prostate cancer, intestinal cancer, liver cancer, leukemia, stomach cancer, cervical cancer and oral epithelial cancer in vitro, especially for lung cancer and prostate cancer cells.

The present invention relates to a culture media system that is useful for the isolation and epigenetically stable propagation of normal stem cells in culture which are derived from columnar epithelial tissues and cancer stem cells from epithelial cancers. In certain embodiments, the culture system is a feeder-free system.

The present invention provides a method for determination of presence or absence of an epithelial cancer-derived cell in a biological sample obtained from a subject comprising the steps of: extracting DNA from the biological sample, analyzing methylation status of a CpG site located in at least one region represented by base sequences SEQ ID NOs: 1, 2, 3 and 4 in the DNA obtained from the step of extracting, and determining presence or absence of the epithelial cancer-derived cell in the biological sample based on an analysis result obtained from the step of analyzing.

The medicine for preventing and / or treating oral epithelial cancer consists of Scorpionidae extract and pharmaceutically acceptable carrier. The Scorpionidae extract is prepared through eliminating poison gland of Scorpionidae, grinding, adding distilled water or glucose solution via stirring, precipitating, centrifuging to obtain supernatant, and freeze drying to obtain freeze dried powder. The medicine may be prepared into different forms for preventing and / or treating oral epithelial cancer effectively, and is non-toxic and safe.

Amplification of the ANXA9 gene in human chromosomal region 1q21 in epithelial cancers indicates a likelihood of both in vivo drug resistance and metastasis, and serves as a biomarker indicating these aspects of the disease. ANXA9 can also serve as a therapeutic target. Interfering RNAs (iRNAs) (such as siRNA and miRNA) and shRNA adapted to inhibit ANXA9 expression, when formulated in a therapeutic composition, and delivered to cells of the tumor, function to treat the epithelial cancer.

This invention relates to 2, 3, 4, 5-tetrasubstituted phenyl propylene derivatives with cytotoxicity. This invention also relates to a method for preparing the derivatives, their drug compositions, and their pharmaceutical application. The derivatives can inhibit the bioactivity of prostate cancer cell (PC-3), nasopharyngeal cancer cell (CNE), oral epithelial cancer cell (KB), lung cancer cell (A549), liver cancer cell (BEL-7404), and cervical cancer cell (Hela), thus can be used as anti-tumor drugs.

The present invention relates to the use of a mitochondrially targeted antioxidant, e.g. derivatives of vitamin E, coenzyme Q10 or a glutathione peroxidase mimetic, in the treatment and prevention of liver diseases and / or epithelial cancers. The present invention also relates to pharmaceutical compositions containing the antioxidant(s) intended for such use. Furthermore the invention relates to the manufacture of medicaments containing the antioxidant(s) useful for such prevention and treatment.